Palvella Therapeutics Inc. (PVLA)
NASDAQ: PVLAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PVLA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.09B
- EPS (TTM)
- -$5.53
- Dividend yield
- None
- 52-week range
- 72.23 – 179.95
- Day range
- 142.22 – 148.69
- Volume / Avg
- 192.67K / 240.41K
- Beta
- —
- Shares outstanding
- 14.62M
52-week range
PVLA stock today
Palvella Therapeutics (PVLA) closed at $142.85 on Nov 20, down 2.00% (-$2.92), versus the S&P 500's 3.70% decline. Shares are 20.6% below their 52-week high of $179.95, set on Nov 9, 2026 and 97.8% above the 52-week low of $72.23, in the middle of the past year's range. PVLA is up 36.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 51.8%.
Palvella Therapeutics has posted a net loss over the last twelve months (EPS of -$5.53), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Palvella Therapeutics
Company profilePalvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Wesley H. Kaupinen
- Headquarters
- Wayne, PA
- Employees
- 29
- Website
- palvellatx.com
Financial highlights
Full financialsPalvella Therapeutics reported a net loss of $41.7 million, compared with a loss of $17.4 million a year earlier. Diluted earnings per share came in at -$3.71.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $42.81M | $25.90M | $31.42M |
| Growth | — | — | +65.28% | -17.56% | +7.14% |
| Net income | $-41.72M | $-17.43M | $18.69M | $-33.28M | $-45.74M |
| EPS (diluted) | $-3.71 | $-7.83 | $2.17 | — | $-0.71 |
Analyst forecast
ForecastConsensus (17 analysts)
strong_buy
Avg. price target
$233.44+63.42%
- Strong buy 0
- Buy 17
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-1.70 vs $-1.65
- Surprise
- -3.03%
PVLA news
All PVLA news- Palvella Therapeutics Announces QTORIN™ Docetaxel, a New QTORIN™ Program for the Treatment of Extramammary Paget’s Disease (EMPD)GlobeNewswire
- Palvella Therapeutics to Host Webcast to Introduce New QTORIN™ ProgramGlobeNewswire
- Leerink Partners Initiates Coverage of Palvella Therapeutics at OutperformNasdaq
- Palvella Therapeutics GAAP EPS of -$1.70 beats by $0.07Seeking Alpha
- Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire
- Palvella Therapeutics to Participate in the Stifel 2026 Healthcare ConferenceGlobeNewswire
- Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date SetGlobeNewswire
- Why is Palvella Therapeutics stock sliding 3% today?Investing.com
Palvella Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LKFTLakefront Biotherapeutics ADR | 33.31 | -0.24% | $2.18B | vs PVLA |
| AUPHAurinia Pharmaceuticals Inc | 14.70 | -1.28% | $1.97B | vs PVLA |
| NAMSNewAmsterdam Pharma Company N.V. | 18.41 | -5.64% | $2.21B | vs PVLA |
| PRGOPerrigo Company plc | 15.94 | -0.62% | $2.21B | vs PVLA |
| PHVSPharvaris N.V. | 31.28 | -1.20% | $2.21B | vs PVLA |
| RCUSArcus Biosciences Inc. | 15.62 | -1.01% | $2.25B | vs PVLA |
| HRMYHarmony Biosciences Holdings Inc. | 32.59 | -1.18% | $1.91B | vs PVLA |
| TRVITrevi Therapeutics Inc. | 13.35 | -2.70% | $1.90B | vs PVLA |
Indexes, lists and sector
Palvella Therapeutics stock FAQ
What is Palvella Therapeutics's stock price today?
PVLA last traded at $142.85 as of Nov 20, 4:00 PM EST, down 2.00% on the day. Prices are delayed at least 15 minutes.
Does Palvella Therapeutics pay a dividend?
No. Palvella Therapeutics does not currently pay a regular cash dividend.
Who is Palvella Therapeutics's CEO?
Mr. Wesley H. Kaupinen is the chief executive officer of Palvella Therapeutics Inc., which has about 29 employees.
Has PVLA ever split its stock?
Yes. The most recent PVLA stock split was a 1-for-80 split on Apr 23, 2024.
What is the PVLA 52-week high?
The 52-week high for PVLA is $179.95 and the 52-week low is $72.23. The stock is currently 20.6% below its high.